Uncategorized

MONTREAL, June 1st 2022 – Replicor Inc., presented updated clinical data from its expanded compassionate use program for treating chronic HBV / HDV co-infection in cirrhotic patients at the 2022 Science of HBV Cure Conference held May 30 – June 2, 2022 in Singapore (see here). Replicor’s expanded use program currently focuses on cirrhotic patients…

MONTREAL, May 2nd, 2022 – Replicor Inc., announced the participation of its CSO, Dr. Andrew Vaillant, atthe 2nd Annual CHB Drug Development Congress, held April 25 – 27th, 2022 in Boston, MA, USA (click here). Dr. Vaillant presented updates in the field on the following important topics: Understanding of the relative impact and mechanisms of…

Replicor successfully confirms NAPs target Hepatitis B subviral particles MONTREAL, April 4th, 2022 – Replicor Inc., announced the successful confirmation of the targeting of Hepatitis B subviral particles (SVP) by NAPs in its REP 301 and REP 401 clinical studies. Clearance of SVP during therapy is required to achieve functional cure of HBV; circulating HBsAg…

Replicor announces post-mortem analysis of ALG-10133 failure MONTREAL, March 30th, 2022 – Replicor Inc., a privately held biopharmaceutical company targeting functional cure for patients with chronic hepatitis B and D infection, announced the publication of its post-mortem analysis of the LNA-modified NAPs following the termination of their development by Aligos Therapeutics in the journal Molecular…

Replicor announces transition of REP 2139-Mg to subcutaneous administration at AASLD 2021 MONTREAL, November 1st, 2021 – Replicor Inc., a privately held biopharmaceutical company targeting functional cure for patients with chronic hepatitis B and D infection, announced four abstracts accepted for presentation at the 2021 meeting of the American Association for the Study of the…

MONTREAL, July 12th, 2021 – Replicor Inc., a privately held biopharmaceutical company targeting functional cure for patients with chronic hepatitis B and D infection, announced the publication of the experimental biomarker analysis from its REP 401 study in Hepatology Communications. The article, entitled “Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP-Based…

MONTREAL, April 26th, 2021 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, announces the publication of an invited review article by its CSO, Dr. Andrew Vaillant entitled “Transaminase Elevations during Treatment of Chronic Hepatitis B…

MONTREAL, February 15th, 2021 – Replicor Inc., a privately held biopharmaceutical company targeting functional cure for patients with chronic hepatitis B and D infection, announced the publication of the analysis of the clinical benefit of transaminase flares in its REP 401 study in the Journal of Viral Hepatitis. Hepatology Communications. The article, entitled “Benefit of…

MONTREAL, December 14th, 2020 – Replicor Inc., a privately held biopharmaceutical company targetinga cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) coinfection, announces the publication of an invited review article by its CSO, Dr. Andrew Vaillant entitled“HBsAg, Subviral Particles, and Their Clearance in Establishing a Functional…

MONTREAL, November 16th, 2020 – Replicor Inc., a privately held biopharmaceutical company targeting functional cure for patients with chronic hepatitis B and D infection, announced the publication of the final results of the long term follow-up of its REP 301 study (REP 301-LTF study) in Hepatology Communications. The article, entitled “Persistent control of HBV and…